CL2023001049A1 - Procedimiento para la fabricación de compuestos orgánicos - Google Patents

Procedimiento para la fabricación de compuestos orgánicos

Info

Publication number
CL2023001049A1
CL2023001049A1 CL2023001049A CL2023001049A CL2023001049A1 CL 2023001049 A1 CL2023001049 A1 CL 2023001049A1 CL 2023001049 A CL2023001049 A CL 2023001049A CL 2023001049 A CL2023001049 A CL 2023001049A CL 2023001049 A1 CL2023001049 A1 CL 2023001049A1
Authority
CL
Chile
Prior art keywords
manufacture
organic compounds
procedure
present application
relates generally
Prior art date
Application number
CL2023001049A
Other languages
English (en)
Inventor
Xiouras Christos
Mukherjee Subha
p gallagher William
Robert Jamison Christopher
S Wei Carolyn
Kolotuchin Sergei
Singh Amarjit
Cuniere Nicolas
SFOUGGATAKI Chris
Ortiz Adrian
R Wisniewski Steven
Zheng Bin
Y Luo Helen
François Emmanuel Lemaire Sébastien
Ben Haïm Cyril
Chernichenko Kostiantyn
Fernando Domenico Broggini Diego
Albert Wagschal Simon
Chi Trung Cao Duy
Reuter Karl
Schmalzbauer Björn
Koschker Philipp
D Eastgate Martin
Skliar Dimitri
Zhdanko Alexander
Penfield Mower Matthew
Duc Tran Ngoc
Rahmani Ramdane
Jean-Marie Jusseau Xavier
Matcha Kiran
Alessandro Perego Luca
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of CL2023001049A1 publication Critical patent/CL2023001049A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/72—Copper
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente solicitud se refiere en general a varios procesos para la fabricación de compuestos orgánicos.
CL2023001049A 2020-10-12 2023-04-12 Procedimiento para la fabricación de compuestos orgánicos CL2023001049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063090558P 2020-10-12 2020-10-12

Publications (1)

Publication Number Publication Date
CL2023001049A1 true CL2023001049A1 (es) 2023-09-22

Family

ID=78536589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001049A CL2023001049A1 (es) 2020-10-12 2023-04-12 Procedimiento para la fabricación de compuestos orgánicos

Country Status (17)

Country Link
US (1) US20230416252A1 (es)
EP (1) EP4225757A1 (es)
JP (1) JP7844457B2 (es)
KR (1) KR20230106611A (es)
CN (1) CN117120418A (es)
AR (1) AR123762A1 (es)
AU (1) AU2021360411A1 (es)
BR (1) BR112023006200A2 (es)
CA (1) CA3195024A1 (es)
CL (1) CL2023001049A1 (es)
CO (1) CO2023005883A2 (es)
IL (1) IL301889A (es)
MX (1) MX2023004237A (es)
PE (1) PE20231310A1 (es)
TW (1) TW202229280A (es)
UY (1) UY39469A (es)
WO (1) WO2022081473A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2760821T3 (es) * 2014-01-31 2018-03-10
SG10201908467RA (en) * 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
WO2016015593A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
NO2721243T3 (es) * 2014-10-01 2018-10-20
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CN110343089A (zh) 2018-04-02 2019-10-18 上海美悦生物科技发展有限公司 苯并咪唑类衍生物及其药学用途
BR112021020368A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona

Also Published As

Publication number Publication date
TW202229280A (zh) 2022-08-01
PE20231310A1 (es) 2023-08-24
AU2021360411A1 (en) 2023-06-08
JP7844457B2 (ja) 2026-04-13
KR20230106611A (ko) 2023-07-13
UY39469A (es) 2022-04-29
JP2023545129A (ja) 2023-10-26
WO2022081473A1 (en) 2022-04-21
AR123762A1 (es) 2023-01-11
EP4225757A1 (en) 2023-08-16
CO2023005883A2 (es) 2023-08-09
CN117120418A (zh) 2023-11-24
IL301889A (en) 2023-06-01
CA3195024A1 (en) 2022-04-21
BR112023006200A2 (pt) 2023-05-09
US20230416252A1 (en) 2023-12-28
AU2021360411A9 (en) 2024-06-06
MX2023004237A (es) 2023-07-03

Similar Documents

Publication Publication Date Title
CL2023001049A1 (es) Procedimiento para la fabricación de compuestos orgánicos
MX2020011565A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
BR112014030365A2 (pt) síntese de composto antiviral
JOP20210285A1 (ar) مركبات 4h-بيرولو[3، 2-جـ]بيريدين-4-ون
MX2019014907A (es) Sintesis de derivados de fosfato.
MX385690B (es) Método novedoso para producir 4,5-dihidroisoxazol 5,5-disustituido.
CU23757B7 (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
CL2021000903A1 (es) Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
PY2242414A (es) Intermedio novedoso para la preparación de piroxasulfona
MX2022006320A (es) Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa.
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
MX2021007536A (es) Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo.
CL2020000190A1 (es) Inhibidores de ror-gamma.
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
MX2020009462A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
CO2020003424A2 (es) Cristal
MX2023013179A (es) Metodos para elaborar un modulador de hemoglobina.
BR112018074287A2 (pt) processo para preparação de eribulina e intermediários da mesma
FR3041658B1 (fr) Procede de production de l-methionine
CL2023001760A1 (es) Proceso
MX2019000984A (es) Proceso para preparacion de indanonas.
BR112022002459A2 (pt) Processo para a preparação de 2-cloro-1-(2-clorotiazol-5-il)etanona